Evidence map›Paper›PMID 39991705›Full record

ArticleFrontiers in medicine2024

Case report: ZFYVE19 gene mutation is associated with familial cholestasis.

Mei-Yan Xue, Ling-Ling Huang, Yue-Yong Zhu, Qi Zheng

Abstract readCase Reports
In one paragraph

Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Repurposing metformin for choriocarcinoma: targeting the AMPK/mTOR pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mei-Yan Xue *Department of Hepatology, Fujian Clinical Research Center for Hepatopathy and Intestinal Diseases, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Ling-Ling Huang *Department of Hepatology, Fujian Clinical Research Center for Hepatopathy and Intestinal Diseases, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Yue-Yong ZhuDepartment of Hepatology, Fujian Clinical Research Center for Hepatopathy and Intestinal Diseases, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Qi ZhengDepartment of Hepatology, Fujian Clinical Research Center for Hepatopathy and Intestinal Diseases, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The etiology of cholestatic liver disease is complex, with clinical manifestations being nonspecific, and biochemical abnormalities mainly characterized by elevated alkaline phosphatase (ALP) and glutamyl transpeptidase (GGT). Due to the lack of specific symptoms and diverse causes, the diagnosis poses certain challenges. Here, we present a case of liver cirrhosis with predominant cholestatic features of unknown etiology. Despite multiple comprehensive routine etiological screenings and liver biopsies, the diagnosis remained unclear. Subsequent whole exome sequencing revealed the diagnosis of liver cirrhosis caused by familial cholestasis related to a mutation in the ZFYVE19 gene. Through this case report analysis, we aim to broaden the diagnostic approach for cholestatic liver disease of unknown etiology, identify the cause accurately, and intervene promptly.

Indexed as

cholestasisgene detectionhereditaryliver cirrhosisZFYVE19

Identifiers

PMID39991705
PMCPMC11843454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.